Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A peptide aptamer to antagonize BCL-6 function.

A Chattopadhyay1, S A Tate, R W Beswick

  • 1MRC Cancer Cell Unit, Hutchison/MRC Research Centre, Cambridge, UK.

Oncogene
|December 7, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ApoA-I mimetics favorably impact cyclooxygenase 2 and bioactive lipids that may contribute to cardiometabolic syndrome in chronic treated HIV.

Metabolism: clinical and experimental·2021
Same author

Physics-informed machine learning: case studies for weather and climate modelling.

Philosophical transactions. Series A, Mathematical, physical, and engineering sciences·2021
Same author

The quality of life index: a pilot study integrating treatment efficacy and quality of life in oncology.

NPJ breast cancer·2020
Same author

Hemorrhagic Neurologic Manifestations in COVID-19: An Isolated or Multifactorial Cause?

AJNR. American journal of neuroradiology·2020
Same author

Classical hand radiology of Gout, Osteoarthritis and Diffuse Idiopathic Skeletal Hyperostosis (DISH).

QJM : monthly journal of the Association of Physicians·2020
Same author

Intestinal leishmaniasis.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2020
Same journal

Aberrant splicing in human cancer shows possible functional impact on transcription factors.

Oncogene·2026
Same journal

The crosstalk between RNA m6A modification and protein lactylation: emerging insights into tumor progression.

Oncogene·2026
Same journal

Correction: Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway.

Oncogene·2026
Same journal

Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer.

Oncogene·2026
Same journal

Histone lactylation-driven IGF2BP3 promotes intrahepatic cholangiocarcinoma progression via SPP1/CD44-dependent macrophage polarization.

Oncogene·2026
Same journal

Correction: SIRT7 activates p53 by enhancing PCAF-mediated MDM2 degradation to arrest the cell cycle.

Oncogene·2026
See all related articles

Researchers developed Apt48, a peptide aptamer targeting the BCL-6 POZ domain, to inhibit BCL-6 activity in lymphoma. This novel approach shows promise for treating BCL-6-driven cancers by restoring normal cell function.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Immunology

Background:

  • BCL-6 is a crucial transcription factor for germinal center B-cell development.
  • BCL-6 dysregulation is implicated in diffuse large B-cell lymphoma, non-Hodgkin's lymphoma, and breast cancer.
  • BCL-6 functions as a transcriptional repressor via its N-terminal POZ domain.

Purpose of the Study:

  • To identify novel inhibitors of BCL-6 activity by targeting its POZ domain.
  • To develop peptide aptamers that specifically disrupt BCL-6 POZ domain interactions.
  • To evaluate the therapeutic potential of these aptamers in BCL-6-driven malignancies.

Main Methods:

  • Screening a peptide aptamer library for binders to the BCL-6 POZ domain.
  • Characterizing the binding interaction of Apt48 with BCL-6 POZ.

Related Experiment Videos

  • Assessing the functional effects of Apt48 on BCL-6-mediated gene repression using a luciferase reporter assay.
  • Evaluating Apt48's impact on B-cell differentiation markers and cytokine-mediated growth arrest.

    • Main Results:

    • Identified Apt48, a peptide aptamer that specifically binds to the BCL-6 POZ domain.
    • Apt48 inhibits BCL-6-mediated transcriptional repression.
    • Expression of Apt48 increased differentiation markers (CD69, Blimp-1, cyclin D2) in B-cell lines.
    • Apt48 restored cytokine-mediated growth arrest in BCL-6 overexpressing cells.

    Conclusions:

    • A peptide aptamer, Apt48, has been developed that antagonizes BCL-6 function.
    • Apt48 disrupts a critical function of BCL-6 required to inhibit B-cell differentiation.
    • This study presents a novel strategy for targeting BCL-6 in lymphoma and other cancers.